Drug news
Afinitor fails Phase III trial for Liver Cancer
Novartis announced that results of a global Phase III study (EVOLVE-1) showed that Afinitor (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic Hepatocellular Carcinoma after progression on or intolerance to sorafenib. Hepatocellular Carcinoma, an aggressive and debilitating cancer, is the most common type of liver cancer. Novartis will not proceed with regulatory filings of Afinitor in this indication.